World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
48
Citations
9639
World Ranking
4418
National Ranking
2006

Overview

Daniel A. Scott is affiliated with Pfizer in the United States. Their research primarily focuses on medicine, with a significant emphasis on epidemiology, where they have contributed the majority of their work. Other subfields include public health, environmental and occupational health, immunology, pulmonary and respiratory medicine, and microbiology.

The scientist's work concentrates on topics related to pneumonia and respiratory infections, respiratory viral infections research, and Pneumocystis jirovecii pneumonia detection and treatment. Additional topics include influenza virus research studies, immunodeficiency and autoimmune disorders, bacterial infections and vaccines, as well as neonatal and maternal infections.

Frequent co-authors in their publications include William C. Gruber, Wendy Watson, Yahong Peng, Kathrin U. Jansen, and Ingrid L. Scully.

Publications by Daniel A. Scott have appeared in various venues, with the highest number in Open Forum Infectious Diseases. Other prominent journals include Vaccine, Human Vaccines & Immunotherapeutics, The Pediatric Infectious Disease Journal, and Clinical Infectious Diseases.

Recent notable papers include:

  • Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age, 2020, Clinical Infectious Diseases
  • Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years, 2021, Clinical Infectious Diseases
  • Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study, 2022, New England Journal of Medicine
  • Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial, 2020, The Lancet Infectious Diseases
  • Potential for Maternally Administered Vaccine for Infant Group B Streptococcus, 2023, New England Journal of Medicine

Best Publications

  • Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

    Marc J.M. Bonten;Susanne M. Huijts;Marieke Bolkenbaas;Chris Webber

  • Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

    Ron Dagan;Scott Patterson;Christine Juergens;David Greenberg

  • Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

    Sylvia H Yeh;Alejandra Gurtman;David C Hurley;Stan L Block

  • Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

    Lisa A. Jackson;Alejandra Gurtman;Martin van Cleeff;Kathrin U. Jansen

  • Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

    Lisa A. Jackson;Alejandra Gurtman;Kathryn Rice;Karlis Pauksens

  • Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine

    Kristina A Bryant;Stan L Block;Sherryl A Baker;William C Gruber

  • Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

    Dorothee M. Kieninger;Kathrin Kueper;Katrin Steul;Christine Juergens

  • Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously

    Fernando Güereña-Burgueño;Eric R. Hall;David N. Taylor;Frederick J. Cassels

  • Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

    Susanna Esposito;Susan Tansey;Allison Thompson;Ahmad Razmpour

  • Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

    Lisa A. Jackson;Alejandra Gurtman;Martin van Cleeff;Robert W. Frenck

  • Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

    Richard N. Greenberg;Alejandra Gurtman;Robert W. Frenck;Cynthia Strout

  • Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

    Unknown

  • Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults☆☆☆

    Daniel A. Scott;Steven F. Komjathy;Branda T. Hu;Sherryl Baker

  • Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

    Unknown

  • Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.

    Donald Hurley;Carl Griffin;Mariano Young;Daniel A Scott

  • Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

    David R. Tribble;Shahida Baqar;Daniel A. Scott;Michael L. Oplinger

  • Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.

    Matthew D. Snape;Chaam L. Klinger;Elvis D. Daniels;Tessa M. John

  • Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

    Catherine Cordonnier;Per Ljungman;Christine Juergens;Johan Maertens

  • Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.

    Judith Absalon;Nathan Segall;Stan L Block

  • Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.

    Allison Thompson;Erik Lamberth;Joseph Severs;Ingrid Scully

  • Vaccines against Campylobacter jejuni.

    Daniel A. Scott

  • IS1414, an Escherichia coli Insertion Sequence with a Heat-Stable Enterotoxin Gene Embedded in a Transposase-Like Gene

    Annette McVeigh;Annette McVeigh;Alessio Fasano;Daniel A. Scott;Sandra Jelacic

  • Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.

    William C. Gruber;Daniel A. Scott;Emilio A. Emini

Frequent Co-Authors

William C. Gruber
William C. Gruber Pfizer (United States)
Emilio A. Emini
Emilio A. Emini Pfizer (United States)
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Robert W. Frenck
Robert W. Frenck Cincinnati Children's Hospital Medical Center
Ron Dagan
Ron Dagan Ben-Gurion University of the Negev
Marc J. M. Bonten
Marc J. M. Bonten Utrecht University
David Greenberg
David Greenberg Ben-Gurion University of the Negev
Noga Givon-Lavi
Noga Givon-Lavi Ben-Gurion University of the Negev
Diederick E. Grobbee
Diederick E. Grobbee Utrecht University
Paul T. Heath
Paul T. Heath St George's, University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Immunology in the USA opens doors to various healthcare careers, including specialized nursing roles. For those interested in mental health, exploring the best online pmhnp programs can lead to rewarding clinical placements and valuable hands-on experience.

Cost is often a major consideration. Prospective students seeking budget-friendly options may find a list of cheap psych np programs helpful as they plan their education without compromising quality.

Career advancement paths such as obtaining a Doctor of Nursing Practice (DNP) degree can significantly impact earnings. Understanding the doctor of nursing practice salary by state allows professionals to make informed decisions about where to work post-graduation.

For nurses currently working as Family Nurse Practitioners, specialized training through acnp programs enables a transition into acute care, broadening clinical expertise and expanding career opportunities.

Best Scientists Citing Daniel A. Scott

Trending Scientists